Jpmorgan Chase & CO Dia Medica Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.51 Trillion
- Q3 2025
A detailed history of Jpmorgan Chase & CO transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 12,785 shares of DMAC stock, worth $76,198. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,785
Previous 12,785
-0.0%
Holding current value
$76,198
Previous $87,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding DMAC
# of Institutions
81Shares Held
8.02MCall Options Held
19.6KPut Options Held
16.5K-
Israel Englander Millennium Management LLC | New York, Ny1.19MShares$7.08 Million0.0% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX875KShares$5.22 Million11.8% of portfolio
-
Geode Capital Management, LLC Boston, MA712KShares$4.24 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA665KShares$3.96 Million0.0% of portfolio
-
Morgan Stanley New York, NY580KShares$3.45 Million0.0% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $158M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...